IVA
Inventiva
Stock NASDAQ – Stock Market Prices, News & Analysis
French biopharmaceutical company specializing in the development of innovative treatments for metabolic diseases and rare disorders.
Inventiva
IVA
French biopharmaceutical company specializing in the development of innovative treatments for metabolic diseases and rare disorders.
Price history of Inventiva
Price history of Inventiva
Performance & Momentum
Inventiva Resumes Trading After $150M US Fundraising
Inventiva, a biopharmaceutical company specializing in oral therapies for metabolic steatohepatitis (NASH), has resumed trading of its ordinary shares on Euronext Paris following a temporary suspension. The company completed a capital increase via American Depositary Shares (ADS) of approximately $150 million, exceeding the initially planned amount. This fundraising aims to strengthen financial resources to support clinical development. Analysts remain confident with stable valuation despite a slight risk adjustment, which may support Inventiva's stock momentum in the medium term.
Strategic Analysis
Inventiva • 2026
Inventiva is a French biopharmaceutical company focused on the clinical development of treatments for metabolic diseases and certain rare conditions. Its positioning is based on a niche specialization, with value creation largely tied to the progress of its research programs and the clinical validation of its pipeline.
- Targeted expertise in medical indications with high unmet needs, which can enhance the potential value of assets under development
- Niche positioning in biopharma, with a more pronounced differentiation profile than that of generalist pharmaceutical companies
- Momentum has turned favorable again, suggesting renewed market interest in the story
- High dependence on the success of clinical trials and regulatory milestones, with significant binary risk
- Still-fragile long-term stock market track record, reflecting strong sensitivity to operational setbacks or funding disappointments
Momentum is strong and reflects a clear recovery trend, with a recently positive underlying trend across several time horizons. For a retail investor, this signals a return of confidence in a speculative name, but the strategic view remains cautious: valuation depends first and foremost on clinical execution and on the ability to turn scientific progress into lasting value creation.
Similar stocks to Inventiva
Take control
of your investments
Track your portfolios, analyze your performance and receive personalized insights to invest with strategy.
- Real-time multi-portfolio tracking
- AI analysis of your positions
- Counter your cognitive biases
